منابع مشابه
Familial Acute Myelogenous Leukemia: Report of Three Cases
Acute myelogenous leukemia (AML) is a hematological malignancy, which accounts for about 15-25% of childhood's leukemia. Genetic factor is one of the most important predisposing elements in childhood acute leukemia, especially AML. In this case report, a rare presentation of familial AML is presented in three monozygotic triplets. Two were 10 months old, and the other one was 16 months old at p...
متن کاملAcute Myelogenous Leukemia
Acute myeloid leukemia is not a single disease but a group of neoplastic disorders. The malignant cells gradually replace, and inhibit the growth and maturation of, normal erythroid, myeloid, and megakaryocytic precursors. Included among the names for this condition are acute myelogenous leukemia, acute myelocytic leukemia, acute myeloid leukemia, acute myeloblastic leukemia, acute granulocytic...
متن کاملAcute Myelogenous Leukemia
Documented central nervous system (CNS) involvement in acute myelogenous leukemia (AML), unlike acute lymphocytic leukemia, is relatively uncommon [1 , 2] . CNS involvement in AML is reported to occur in 6%-17% of cases [1-4]. It is expected that improvements in therapy with increased frequency of remission and prolonged survival will lead to further increases in clinical CNS involvement in AML...
متن کاملTreatment of Acute Myelogenous Leukemia
There have been significant advances in our understanding of the biology of acute myelogenous leukemia (AML), and to a lesser extent, in its treatment. Dr. Estey has provided an excellent overview of the current state of the clinical management of the disease. He has described both the standard therapeutic approaches, including allogeneic hematopoietic stem cell transplantation, as well as the ...
متن کاملTreatment of acute myelogenous leukemia.
The treatment of patients with acute myelogenous leukemia (AML) ranges from palliative care only, to standard therapy, to investigational approaches. Acute myelogenous leukemia is, in fact, several different diseases, and the percentage of clinical responses varies with disease and prognostic subsets. A high proportion of AML patients remain refractory to primary treatment or relapse later. Thi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Baylor University Medical Center Proceedings
سال: 2008
ISSN: 0899-8280,1525-3252
DOI: 10.1080/08998280.2008.11928364